The global Tonic-Clonic Seizure Market is poised to experience significant growth in revenue due to the increasing prevalence of epilepsy and other neurological disorders. According to the World Health Organization (WHO), epilepsy accounts for more than 0.5% of the disease burden worldwide, affecting approximately 4 to 10 out of every 1,000 individuals with active epilepsy or ongoing seizures requiring treatment. The market's growth is also driven by the fact that seizures can be managed effectively with the proper administration of antiseizure medications, and up to 70% of epilepsy patients can achieve seizure-free status.
A tonic-clonic seizure is a type of epileptic seizure characterized by the presence of both tonic and clonic seizure features. The tonic phase involves muscle stiffness, a cry or moan caused by the expulsion of air past the vocal cords, falling down, tongue or cheek biting, and the presence of saliva mixed with a small amount of blood. This is followed by the clonic phase, during which the limbs jerk rhythmically and rapidly, with bending and relaxation of the elbows, hips, and knees. Eventually, the jerking subsides and stops. Tonic-clonic seizures can occur in any age group, either as isolated episodes or as a chronic and recurrent condition (epilepsy). Some seizures may be triggered by psychological issues (psychogenic).
Get free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/5346
Several factors contribute to the growth of the tonic-clonic seizure market:
Drivers:
- Increased incidence of epilepsy: According to the National Institute of Health, approximately 11% of Americans experience seizures at some point in their lives. Seizures account for 1% to 2% of all emergency room visits in the United States. Males are 1.85 times more likely to experience acute symptomatic seizures than females, with a lifetime risk of 5.0% for men and 2.7% for women.
- Increased awareness and demand for treatment: Collaborative efforts by various organizations, institutions, and governments have led to heightened awareness and demand for epilepsy treatment, reducing the stigma associated with the condition. WHO, the International League Against Epilepsy (ILAE), and the International Bureau for Epilepsy (IBE) have jointly launched a global campaign against epilepsy to raise public and private efforts in improving care and reducing the burden of the disease. As a result, epilepsy has become a priority in many countries, leading to regional declarations in each of the six WHO regions.
- Expanded product pipeline: Increased clinical trial activity, technological advancements, and higher investments in research and development have facilitated the development of novel treatment options. Improved healthcare infrastructure and increased healthcare budgets are also expected to support market growth.
Restraints:
- Stigma and discrimination: Epilepsy and seizures are often accompanied by social stigma, discrimination, misinformation, and fear in many parts of the world. People with epilepsy and their families frequently experience stigma and discrimination, compromising their quality of life. The societal stigma associated with the condition may discourage individuals from seeking treatment due to the fear of identification.
- Lack of access to proper care: Nearly 80% of people with epilepsy reside in low- and middle-income countries, and 75% of patients do not receive adequate care. This lack of access to proper treatment is a significant factor impeding market growth.
Opportunities:
- Increasing seizure frequency: The growing prevalence of seizures creates opportunities for the tonic-clonic seizure market, as continuous treatment is required for this chronic condition. Additionally, the expansion of healthcare infrastructure, advancements in technology, and the use of advanced imaging technology for early diagnosis contribute to market growth. Rising research and development expenditure in the epilepsy market, with a focus on developing novel treatments for tonic-clonic seizures and demand for more effective medications, also present growth opportunities.
- Awareness campaigns: Various organizations running awareness campaigns create additional avenues for market expansion. Initiatives such as the WHO Program on Reducing Epilepsy Treatment Gap and the Mental Health Gap Action Programme (mhGAP) have successfully improved the capacity of primary care and non-specialist healthcare practitioners to identify, manage, and follow up on epilepsy patients. These programs have enabled 6.5 million more people to access treatment for epilepsy.
Geographically, the North American region is expected to dominate the market due to the high prevalence of tonic-clonic seizures. In the United States, approximately 11% of the population experiences seizures at some point in their lives, and seizures account for a significant portion of emergency room visits. Increased brain damage from road accidents and other causes has led to a rise in post-traumatic epilepsy cases. Furthermore, the growing geriatric population and increased government spending on research and development of seizure medications contribute to market expansion.
The Asia Pacific region is anticipated to experience the fastest growth due to the increasing prevalence of tonic-clonic seizures, growing patient awareness, and improved treatment options. Countries like India, China, and South Korea are focusing on research and development and the development of new products. Healthcare reforms in these countries are also expected to drive market growth by improving the availability, affordability, and quality of healthcare.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/5346
Key Market Trends and Innovation:
- In December 2021, Eisai, Inc. completed phase 3 clinical trials to evaluate the safety and efficacy of its treatment for generalized tonic-clonic seizures in children aged 4 to 12 years.
- Organic and inorganic strategies adopted: In April 2022, the US Food and Drug Administration (USFDA) authorized the Abbreviated New Drug Application (ANDA) of Indoco Remedies' lacosamide injection, an anticonvulsant medication used to treat partial-onset seizures in patients older than 17 years old. In November 2020, UCB S.A. received USFDA approval for VIMPAT (lacosamide), which is used to treat partial-onset seizures and as an adjunctive therapy for managing partial generalized tonic-clonic seizures in patients aged four years and older. This approval expands treatment options for epileptic patients who previously had limited choices. In November 2019, SK Biopharmaceuticals obtained USFDA approval for Cenobamate (Xcopri), which can be taken by adult patients for the management of partial-onset seizures, providing doctors with an effective drug for treating patients with focal seizures.
Key players in the market include SK Biopharmaceuticals, UCB S.A., Novartis AG, GSK Plc, Pfizer Inc., Eisai Co., Ltd., Angelini Pharma, Indoco Remedies Ltd., Upsher Smith Laboratories, LLC., Sun Pharmaceuticals Industries Ltd., Abbott Laboratories, Johnson and Johnson, Sanofi, Alkem Laboratories Ltd., and Marinus Pharmaceuticals Inc.
The report provides historical data, forecasts, and revenue growth at the global, regional, and country levels. It offers analysis of industry trends, consumption patterns, and market strategies for each region, major country, and segment from 2019 to 2030. Additionally, the report includes an industry analysis, competitive landscape, company financials, and impact analysis.
The market is segmented based on product type, route of administration, disease type, treatment, distribution channel, and end-user. The product types include solid dosage forms (tablets and capsules) and liquid dosage forms (injectable and suspension). The route of administration includes parenteral, oral, and others. Disease types consist of generalized tonic-clonic seizures and focal to bilateral tonic-clonic seizures. Treatment options include various medication classes such as barbiturates, hydantoin, phenyltriazine, iminostilbenes, benzodiazepines, and aliphatic carboxylic acid. The distribution channels encompass hospital pharmacies, retail pharmacies, and online pharmacies. Finally, the end-users of the products are hospitals, homecare settings, and clinics.
In terms of regional outlook, North America (including the United States, Canada, and Mexico) is expected to contribute the largest market share. Europe (Germany, UK, France, Italy, Spain, and Benelux) follows suit. The Asia Pacific region, particularly China, India, Japan, and South Korea, is projected to experience rapid growth. Latin America (Brazil) and the Middle East & Africa (Saudi Arabia, UAE, and South Africa) are also part of the market landscape.
In conclusion, the global tonic-clonic seizure market is poised for substantial growth due to the increased prevalence of epilepsy and other neurological disorders. Factors such as improved awareness, growing investments in research and development, and the availability of advanced treatment options drive market expansion. However, challenges related to stigma, inadequate access to care, and limited treatment options in low- and middle-income countries restrain the market. Nevertheless, opportunities lie in the increasing seizure frequency, expanding healthcare infrastructure, and awareness campaigns. The market's geographic scenario highlights North America as the largest market share holder, while the Asia Pacific region demonstrates the highest growth potential. Continued innovation, strategic collaborations, and product development are key trends in the market, with major players actively involved in advancing treatments for tonic-clonic seizures.
Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/5346
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
Browse for more reports:
Anesthesia CO2 Absorbent Market
Anesthesia and Respiratory Devices Market
Injectable Drug Delivery Market
Augmented Reality and Virtual Reality (AR and VR) in Healthcare Market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report